The present disclosure relates generally to the field of medical devices. More particularly, some embodiments relate to medical assemblies and devices for improving blood flow to regions of a patient's body.
The written disclosure herein describes illustrative embodiments that are non-limiting and non-exhaustive. Reference is made to certain of such illustrative embodiments that are depicted in the figures, in which:
Many individuals suffer from insufficient blood flow to regions (e.g., peripheral regions) of their body. For example, some individuals suffering from peripheral artery disease experience narrowing of one or more peripheral arteries (e.g., a superficial femoral artery) to their leg(s) or arm(s). Such narrowing of the arteries may reduce blood flow to one or more peripheral regions. Insufficient blood flow to the extremities of the body can lead to critical limb ischemia, gangrene, and/or amputation. Diabetes is known to increase the risk of peripheral artery disease.
Insufficient blood flow to peripheral regions of a body may result from other causes as well. For example, in addition to atherosclerosis in peripheral arteries, blood flow to a peripheral region may be impeded by some other blockage. In other cases, a portion of an artery may be punctured or weakened, thereby rendering the artery (or a portion of the artery) unsuitable for providing long-term blood flow to a peripheral region.
Embodiments described herein may be used to form a non-natural flow path that improves blood flow to regions of a patient. For example, in some embodiments, a medical device that includes a first graft portion, a second graft portion, and a catheter portion that is coupled to and disposed between the first graft portion and the second graft portion may be inserted into a patient such that the first graft portion is coupled to the vasculature at a first location that is above the knee of a patient, and the second graft portion is coupled to the vasculature at a second location that is below the knee of the patient. The new flow path that is established between the first location and the second location may improve blood flow to a region (e.g., the lower leg or foot) of the patient.
The components described herein may additionally or alternatively be used to establish other non-natural flow paths within a patient. In some embodiments, both ends of the non-natural flow path are coupled to vasculature of the patient. In other embodiments, only one end of the non-natural flow path is coupled to vasculature of the patient. In some embodiments, the non-natural flow path is disposed within the torso region of the patient. In other embodiments, the non-natural flow path is disposed below the waist. In some embodiments, the non-natural flow path extends from above the waist to below the waist. In some embodiments, the non-natural flow path traverses the knee (i.e., connects the upper leg with the lower leg). In some embodiments, one end of the non-natural flow path empties directly into a chamber of the heart. Other suitable locations for non-natural flow paths formed by medical devices described herein are possible and within the scope of this disclosure.
The components of the embodiments as generally described and illustrated in the figures herein can be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of various embodiments, as represented in the figures, is not intended to limit the scope of the present disclosure, but is merely representative of various embodiments. While various aspects of the embodiments are presented in drawings, the drawings are not necessarily drawn to scale unless specifically indicated.
The phrase “coupled to” is broad enough to refer to any suitable coupling or other form of interaction between two or more entities. Thus, two components may be coupled to each other even though they are not in direct contact with each other. For example, two components may be coupled to one another through an intermediate component. The phrase “attached to” refers to interaction between two or more entities which are in direct contact with each other and/or are separated from each other only by a fastener of any suitable variety (e.g., an adhesive).
As used herein, the term “crush force” refers to the magnitude of a two-dimensional force (e.g., pinch force) that is applied perpendicular to the longitudinal axis of a tube that causes deformation of the tube from an unconstrained state to a constrained state in which the distance between opposite sides of the tube is three-quarters of the distance between opposite sides of the tube when the tube is unconstrained. As used herein, the term “hoop force” refers to the magnitude of a force that is uniformly applied around a circumference of a tube to compress the tube to three-quarters of its initial diameter. A “porous tube” is considered to be porous even if the porous tubular structure is coated, disposed between, or embedded within a non-porous polymer. For example, a tubular wire structure that includes openings between adjacent elements of wire is porous even if the tubular wire structure is coated, disposed between, or embedded within a non-porous polymer.
As shown in
Lumen 110 may be synthetic, biologic, or a native vessel. In some embodiments, lumen 110 may be formed from a relatively flexible material. In addition, lumen 110 may be formed from a material that is suitable for anastomosis to a vein or artery of a patient. Suitable materials include, but are not limited to Polytetrafluoroethylene (PTFE), silicone, polyurethane, fluoroelastomers, fluorosilicone, PEBAX, and the like.
In some embodiments, lumen 110 may comprise multiple layers. For example, lumen 110 may have an inner layer formed from a polymer, such as porous PTFE. More specifically, the inner layer may be formed from expanded PTFE or fibrous PTFE. In embodiments that use fibrous PTFE, the fibrous PTFE may be formed by rotation of a spinneret (i.e., rotational spun PTFE) and/or by subjecting a solution or dispersion comprising PTFE to an electric field (i.e., electrospun PTFE).
Lumen 110 may also include an outer (i.e., abluminal) layer. Like the inner layer, the outer layer may be formed from a polymer such as porous PTFE. In some embodiments, the outer layer is configured to permit tissue ingrowth. In some embodiments, the outer layer is identical in composition to the inner layer. In other embodiments, the outer layer and the inner layer differ in composition.
In some embodiments, lumen 110 may include an intervening layer that is disposed between the inner layer and the outer layer. For example, in some embodiments, the intervening layer comprises one or more of silicone, fluorinated ethylene propylene (FEP), and polyether block amide (e.g., PEBAX). In some embodiments, the intervening layer may be an elastomeric material, such as silicone, that allows for resealing of lumen 110 after puncture. In other words, in some embodiments, at least a portion of lumen 110 may be pierced by a needle or other sharp object. Once the needle or other sharp object is retracted from lumen 110, the intervening layer may reseal about the aperture formed by the inserted needle or sharp object, thereby preventing the leakage of blood or other fluid across a wall of lumen 110. Such resealability may permit early cannulation of lumen 110 (e.g., cannulation within one week of implantation). In some embodiments, the silicone layer may be extruded silicone, and form an extruded silicone tube. Extruded silicone may have residual stresses that increase the resealability of the intervening layer. In some embodiments, the silicone layer may be the outer layer of lumen 110. In some embodiments, the silicone layer may be the inner layer of the lumen 110. The elastomeric material may provide increased durability after cannulation resulting in increased life and a smaller biological response. The self-sealing nature of the layer may provide several benefits, such as, reduced thrombus production, increased mechanical integrity of lumen 110, and reduced flow disturbances within lumen 110.
The length of lumen 110 is dependent on the situation in which lumen 110 is used to create a non-natural flow path. As discussed previously, lumen 110 enables a bypass of a narrowed, obstructed, damaged, and/or diseased portion of the patient's vasculature. The length of lumen 110 may be determined by (1) the desired location for placement in the patient and/or (2) the particular anatomy of the patient. The length of lumen 110 may be customizable, and a medical professional may trim the length of lumen 110 to meet the specific situation of a particular patient.
Reinforcing sleeve 120 includes a reinforcing structure 122 that is designed to increase the hoop strength, crush resistance, and longitudinal strength of lumen 110. Reinforcing structure 122 may be formed by braiding, as illustrated in
Reinforcing structure 122 may comprise and/or consist of a metal alloy that is inert in the human body. For example, in some embodiments, reinforcing structure 122 comprises and/or consists of a nickel-titanium alloy, such as nitinol.
Reinforcing sleeve 120 may further include end caps 124 and 126 to prevent fraying of reinforcing structure 122. End caps 124 and 126 may also provide a location for the medical professional to grip reinforcing sleeve 120 and to slide reinforcing sleeve 120 along lumen 110. End caps 124 and 126 may comprise an inert material in a human body, such as silicone, PTFE, etc.
As discussed previously, reinforcing sleeve 120 may be placed on lumen 110 and the position of reinforcing sleeve 120 may be adjusted by sliding reinforcing sleeve 120 relative to lumen 110. To slide reinforcing sleeve 120 along lumen 110, a push force may be applied to reinforcing sleeve 120.
Alternatively, if a pull force is applied to reinforcing sleeve 120, reinforcing sleeve 120 locks up and secures to lumen 110. For example, if a force F3 is applied to end cap 126 in the second direction farthest from force F1 applied in the first direction, as illustrated in
Reinforcing sleeve 120 may be secured to lumen 110 by a number of different methods. After reinforcing sleeve 120 is positioned by the medical professional along lumen 110 to the predetermined position, the medical professional may secure or lock reinforcing sleeve 120 to lumen 110. For example, reinforcing sleeve 120 may be secured to lumen 110 by adhesives, fasteners, and the like. Alternately, reinforcing sleeve 120 may be simply be placed in the predetermined position and secured in place by the braids of reinforcing sleeve 120. In some embodiments, reinforcing structure 122 is configured to allow tissue ingrowth to secure reinforcing sleeve 120 in place. In some embodiments, reinforcing sleeve 120 is not secured to lumen 110, but is simply secured by tissue ingrowth.
In some embodiments, the diameter of end caps 124 and 126 is slightly smaller than the outer diameter of lumen 110. Because the inner diameter of end caps 124 and 126 is slightly smaller than the outer diameter of lumen 110, reinforcing sleeve 120 is secured in the predetermined location. Further, because the inner diameter of end caps 124 and 126 is only slightly smaller than the outer diameter of lumen 110, flow through lumen 110 is only slightly affected or not impacted at all. In some embodiments, end caps 124 and 126 may include an enlarging ring 130.
In some embodiments, medical device 100 may include multiple reinforcing sleeves 120 along lumen 110, as illustrated in
In some embodiments, similar to reinforcing sleeve 120, reinforcing sleeve 220 is configured to slide over lumen 210 and may be positioned to a predetermined location. In some embodiments, reinforcing sleeve 220 may be secured to lumen 210 by clamping, suturing, adhesive, and the like. In some embodiments, reinforcing sleeve 220 may be stretched and tightened on lumen 210 to secure reinforcing sleeve 220. In some embodiments, reinforcing sleeve 220 may be configured to allow tissue ingrowth to help secure reinforcing sleeve 220 in place. In some embodiments, reinforcing sleeve 220 is not secured to lumen 210 but is simply secured by tissue ingrowth. In other embodiments, end caps 224 and 226 (shown on
The length of reinforcing sleeve 220 may be adjusted in a number of different ways. In some embodiments the length of reinforcing sleeve 220 may be adjusted by stretching reinforcing sleeve 220 to make reinforcing sleeve 220 longer. In some embodiments, reinforcing sleeve may be cut or trimmed by a cutting element 230 (scissors, scalpel, etc.), as illustrated in
In some embodiments, as illustrated in
In some embodiments, end caps 224 and 226 may be attachable and detachable from reinforcing structure 222. For example, the medical professional may cut reinforcing structure 222 and remove end cap 224 attached to the trim portion 223 and replace end cap 224 on the uncapped end of reinforcing structure 222. End caps 224 and 226 may comprise an inert material in a human body, such as silicone, PTFE, etc.
In some embodiments, reinforcing sleeve 220 may be bent similar to reinforcing sleeve 120 illustrated in
In some embodiments, medical device 200 may include multiple reinforcing sleeves 220 along lumen 210. In some embodiments, medical device 200 may include different types of reinforcing sleeves, such as a reinforcing sleeve 120 with a braided reinforcing structure and a reinforcing sleeve 220 with a coiled reinforcing structure, as illustrated in
In some embodiments, lumens 110 and 210 may be cannulated through reinforcing sleeves 120 and 220 as braided reinforcing structure 122 and coiled reinforcing structure 222 moves out of the way to enable the needle to pass through lumen 110.
In some embodiments, coiled reinforcing structure 222 may have a higher hoop force than braided reinforcing structure 122. In some embodiments, coiled reinforcing structure 222 may have a higher crush force than braided reinforcing structure 122.
The above disclosure has disclosed braided reinforcing structures 122 and wound reinforcing structures 222. However, the present disclosure is not so limited. Reinforcing sleeves may have a number of different structures to reinforce lumen 110, and it would be apparent to those having skill in the art that changes may be made to the structure of the reinforcing sleeves without departing from the underlying principles of the present disclosure.
Some embodiments relate to a kit for establishing a non-natural flow path within a patient. The kit may include, inter alia, the following components: a lumen 110, a plurality of reinforcing sleeves (e.g., 120, 220, etc.) with a variety of different reinforcing structures (122, 222, etc.) of varying length, cutting element 230, and instructions for creating a non-natural flow path within the patient. Cutting element 230 may be used to adjust the length of lumen 110, 210 or adjust the length of reinforcing sleeves 120 and 220.
In some embodiments, medical device 100, 200, etc., may be inserted into the patient (either percutaneously or through an “open” surgical procedure) and then coupled to the vasculature of the patient via anastomosis at the lateral ends of lumen 110.
Any methods disclosed herein include one or more steps or actions for performing the described method. The method steps and/or actions may be interchanged with one another. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order and/or use of specific steps and/or actions may be modified. Moreover, sub-routines or only a portion of a method described herein may be a separate method within the scope of this disclosure. Stated otherwise, some methods may include only a portion of the steps described in a more detailed method.
Reference throughout this specification to “an embodiment” or “the embodiment” means that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment. Thus, the quoted phrases, or variations thereof, as recited throughout this specification are not necessarily all referring to the same embodiment.
Similarly, it should be appreciated by one of skill in the art with the benefit of this disclosure that in the above description of embodiments, various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. This method of disclosure, however, is not to be interpreted as reflecting an intention that any claim requires more features than those expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following this Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment. This disclosure includes all permutations of the independent claims with their dependent claims.
Recitation in the claims of the term “first” with respect to a feature or element does not necessarily imply the existence of a second or additional such feature or element. It will be apparent to those having skill in the art that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the present disclosure.
This application claims priority to U.S. Provisional Application No. 62/579,228, filed on Oct. 31, 2017 and titled, “SUBCUTANEOUS VASCULAR ASSEMBLIES FOR IMPROVING BLOOD FLOW AND RELATED DEVICES AND METHODS,” which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3357432 | Sparks | Dec 1967 | A |
3435823 | Edwards | Apr 1969 | A |
3490438 | Lavender et al. | Jan 1970 | A |
3683926 | Suzuki | Aug 1972 | A |
3814137 | Martinez | Jun 1974 | A |
3818511 | Goldberg et al. | Jun 1974 | A |
3826257 | Buselmeier | Jul 1974 | A |
3853126 | Schulte | Dec 1974 | A |
3882862 | Berend | May 1975 | A |
3998222 | Shihata | Dec 1976 | A |
4076023 | Martinez | Feb 1978 | A |
4133312 | Burd | Jan 1979 | A |
4184489 | Burd | Jan 1980 | A |
4214586 | Mericle | Jul 1980 | A |
4318401 | Zimmernan | Mar 1982 | A |
4427219 | Madej | Jan 1984 | A |
4441215 | Kaster | Apr 1984 | A |
4447237 | Frisch et al. | May 1984 | A |
4496349 | Cosentino | Jan 1985 | A |
4496350 | Cosentino | Jan 1985 | A |
4503568 | Madras | Mar 1985 | A |
4550447 | Seiler, Jr | Nov 1985 | A |
4619641 | Schanzer | Oct 1986 | A |
4655771 | Wallersten | Apr 1987 | A |
4723948 | Clark et al. | Feb 1988 | A |
4734094 | Jacob et al. | Mar 1988 | A |
4743251 | Barra | May 1988 | A |
4753236 | Healy | Jun 1988 | A |
4771777 | Horzewski et al. | Sep 1988 | A |
4772268 | Bates | Sep 1988 | A |
4786345 | Wood | Nov 1988 | A |
4790826 | Elftman | Dec 1988 | A |
4822341 | Colone | Apr 1989 | A |
4848343 | Wallsten et al. | Jul 1989 | A |
4850999 | Planck | Jul 1989 | A |
4877661 | House et al. | Oct 1989 | A |
4898591 | Jang et al. | Feb 1990 | A |
4898669 | Tesio | Feb 1990 | A |
4917087 | Walsh et al. | Apr 1990 | A |
4919127 | Pell | Apr 1990 | A |
4929236 | Sampson | May 1990 | A |
4955899 | Della Corna et al. | Sep 1990 | A |
5026513 | House et al. | Jun 1991 | A |
5041098 | Loiterman et al. | Aug 1991 | A |
5053023 | Martin | Oct 1991 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5061276 | Tu et al. | Oct 1991 | A |
5064435 | Porter | Nov 1991 | A |
5084065 | Weldon | Jan 1992 | A |
5104402 | Melbin | Apr 1992 | A |
5171227 | Twardowski et al. | Dec 1992 | A |
5171305 | Schickling et al. | Dec 1992 | A |
5192289 | Jessen | Mar 1993 | A |
5192310 | Herweck et al. | Mar 1993 | A |
5197976 | Herweck et al. | Mar 1993 | A |
5282860 | Matsuno et al. | Feb 1994 | A |
5330500 | Song | Jul 1994 | A |
5336616 | Livesey et al. | Aug 1994 | A |
5399168 | Wadsworth | Mar 1995 | A |
5405320 | Twardowski et al. | Apr 1995 | A |
5405339 | Kohnen et al. | Apr 1995 | A |
5454790 | Dubrul | Oct 1995 | A |
5474268 | Yu | Dec 1995 | A |
5474563 | Myler et al. | Dec 1995 | A |
5476451 | Ensminger et al. | Dec 1995 | A |
5496294 | Hergenrother et al. | Mar 1996 | A |
5509897 | Twardowski et al. | Apr 1996 | A |
5549663 | Cottone, Jr. | Aug 1996 | A |
5558641 | Glantz et al. | Sep 1996 | A |
5562617 | Finch, Jr. et al. | Oct 1996 | A |
5562618 | Cai et al. | Oct 1996 | A |
5591226 | Trerotola et al. | Jan 1997 | A |
5607463 | Schwartz et al. | Mar 1997 | A |
5624413 | Markel et al. | Apr 1997 | A |
5637088 | Wenner et al. | Jun 1997 | A |
5637102 | Tolkoff et al. | Jun 1997 | A |
5645532 | Horgan | Jul 1997 | A |
5647855 | Trooskin | Jul 1997 | A |
5669637 | Chitty et al. | Sep 1997 | A |
5669881 | Dunshee | Sep 1997 | A |
5674272 | Bush et al. | Oct 1997 | A |
5676346 | Leinsing | Oct 1997 | A |
5743894 | Swisher | Apr 1998 | A |
5755773 | Schuster | May 1998 | A |
5755775 | Trerotola et al. | May 1998 | A |
5792104 | Speckman et al. | Aug 1998 | A |
5797879 | Decampli | Aug 1998 | A |
5800512 | Lentz et al. | Sep 1998 | A |
5800514 | Nunez et al. | Sep 1998 | A |
5800522 | Campbell | Sep 1998 | A |
5810870 | Myers et al. | Sep 1998 | A |
5830224 | Cohn et al. | Nov 1998 | A |
5840240 | Stenoien et al. | Nov 1998 | A |
5866217 | Stenoien et al. | Feb 1999 | A |
5904967 | Ezaki et al. | May 1999 | A |
5931829 | Burbank et al. | Aug 1999 | A |
5931865 | Silverman et al. | Aug 1999 | A |
5957974 | Thompson et al. | Sep 1999 | A |
5997562 | Zadno-Azizi | Dec 1999 | A |
6001125 | Golds et al. | Dec 1999 | A |
6019788 | Butters et al. | Feb 2000 | A |
6036724 | Lentz et al. | Mar 2000 | A |
6102884 | Squitieri | Aug 2000 | A |
6156016 | Maginot | Dec 2000 | A |
6167765 | Weitzel | Jan 2001 | B1 |
6171295 | Garabedian | Jan 2001 | B1 |
6231085 | Olson | May 2001 | B1 |
6245098 | Feeser | Jun 2001 | B1 |
6261255 | Mullis et al. | Jul 2001 | B1 |
6261257 | Uflacker et al. | Jul 2001 | B1 |
6280466 | Kugler et al. | Aug 2001 | B1 |
6308992 | Mitsui et al. | Oct 2001 | B1 |
6309411 | Lashinski et al. | Oct 2001 | B1 |
6319279 | Shannon et al. | Nov 2001 | B1 |
6338724 | Dossa | Jan 2002 | B1 |
6398764 | Finch, Jr. et al. | Jun 2002 | B1 |
6402767 | Nash et al. | Jun 2002 | B1 |
6428571 | Lentz et al. | Aug 2002 | B1 |
6436132 | Patel et al. | Aug 2002 | B1 |
6582409 | Squitieri | Jun 2003 | B1 |
6585762 | Stanish | Jul 2003 | B1 |
6610004 | Viole et al. | Aug 2003 | B2 |
6689096 | Loubens et al. | Feb 2004 | B1 |
6689157 | Madrid et al. | Feb 2004 | B2 |
6692461 | Wantink | Feb 2004 | B2 |
6699233 | Slanda et al. | Mar 2004 | B2 |
6702748 | Nita et al. | Mar 2004 | B1 |
6702781 | Reifart et al. | Mar 2004 | B1 |
6706025 | Engelson et al. | Mar 2004 | B2 |
6719781 | Kim | Apr 2004 | B1 |
6719783 | Lentz et al. | Apr 2004 | B2 |
6730096 | Basta | May 2004 | B2 |
6733459 | Atsumi | May 2004 | B1 |
6740273 | Lee | May 2004 | B2 |
6749574 | O'Keefe | Jun 2004 | B2 |
6752826 | Holloway et al. | Jun 2004 | B2 |
6758836 | Zawacki | Jul 2004 | B2 |
6858019 | McGuckin, Jr. et al. | Feb 2005 | B2 |
6926724 | Chu | Aug 2005 | B1 |
6926735 | Henderson | Aug 2005 | B2 |
6976952 | Maini et al. | Dec 2005 | B1 |
6981987 | Huxel et al. | Jan 2006 | B2 |
7011645 | McGuckin, Jr. et al. | Mar 2006 | B2 |
7025741 | Cull | Apr 2006 | B2 |
7044937 | Kirwan et al. | May 2006 | B1 |
7101356 | Miller | Sep 2006 | B2 |
7131959 | Blatter | Nov 2006 | B2 |
7211074 | Sansoucy | May 2007 | B2 |
7244271 | Lenz et al. | Jul 2007 | B2 |
7244272 | Dubson et al. | Jul 2007 | B2 |
7252649 | Sherry | Aug 2007 | B2 |
7297158 | Jensen | Nov 2007 | B2 |
7351257 | Kaldany | Apr 2008 | B2 |
7399296 | Poole et al. | Jul 2008 | B2 |
7438699 | Pecor et al. | Oct 2008 | B2 |
7452374 | Hain et al. | Nov 2008 | B2 |
7507229 | Hewitt et al. | Mar 2009 | B2 |
7588551 | Gertner | Sep 2009 | B2 |
7708722 | Glenn | May 2010 | B2 |
7722665 | Anwar et al. | May 2010 | B2 |
RE41448 | Squitieri | Jul 2010 | E |
7762977 | Porter | Jul 2010 | B2 |
7789908 | Sowinski et al. | Sep 2010 | B2 |
7828833 | Haverkost et al. | Nov 2010 | B2 |
7833214 | Wilson et al. | Nov 2010 | B2 |
7846139 | Zinn et al. | Dec 2010 | B2 |
7850675 | Bell et al. | Dec 2010 | B2 |
7850705 | Bach et al. | Dec 2010 | B2 |
7922757 | McGuckin, Jr. | Apr 2011 | B2 |
7972314 | Bizup et al. | Jul 2011 | B2 |
8079973 | Herrig | Dec 2011 | B2 |
8092435 | Beling et al. | Jan 2012 | B2 |
8313524 | Edwin et al. | Nov 2012 | B2 |
8388634 | Rubenstein et al. | Mar 2013 | B2 |
8512312 | Sage | Aug 2013 | B2 |
8551139 | Surti et al. | Oct 2013 | B2 |
8690815 | Porter et al. | Apr 2014 | B2 |
8951355 | Clearflow et al. | Feb 2015 | B2 |
9642623 | Agarwal et al. | May 2017 | B2 |
20010053930 | Kugler et al. | Dec 2001 | A1 |
20020049403 | Alanis | Apr 2002 | A1 |
20020055766 | Wallace et al. | May 2002 | A1 |
20020055771 | Sandock | May 2002 | A1 |
20020099432 | Yee | Jul 2002 | A1 |
20020151761 | Viole et al. | Oct 2002 | A1 |
20030100859 | Henderson et al. | May 2003 | A1 |
20030135258 | Andreas et al. | Jul 2003 | A1 |
20030135261 | Kugler et al. | Jul 2003 | A1 |
20030139806 | Haverkost et al. | Jul 2003 | A1 |
20030181969 | Kugler et al. | Sep 2003 | A1 |
20030212385 | Brenner et al. | Nov 2003 | A1 |
20030212431 | Brady et al. | Nov 2003 | A1 |
20040024442 | Sowinkski et al. | Feb 2004 | A1 |
20040054405 | Thierry et al. | Mar 2004 | A1 |
20040073282 | Stanish | Apr 2004 | A1 |
20040078071 | Escamilla et al. | Apr 2004 | A1 |
20040147866 | Blatter et al. | Jul 2004 | A1 |
20040193242 | Lentz et al. | Sep 2004 | A1 |
20040215058 | Zirps et al. | Oct 2004 | A1 |
20040215337 | Hain et al. | Oct 2004 | A1 |
20040236412 | Brar | Nov 2004 | A1 |
20050004553 | Douk | Jan 2005 | A1 |
20050137614 | Porter et al. | Jun 2005 | A1 |
20050192559 | Michels et al. | Sep 2005 | A1 |
20050203457 | Smego | Sep 2005 | A1 |
20050209581 | Butts et al. | Sep 2005 | A1 |
20050215938 | Khan et al. | Sep 2005 | A1 |
20060004392 | Amarant | Jan 2006 | A1 |
20060029465 | Auer | Feb 2006 | A1 |
20060058867 | Thistle et al. | Mar 2006 | A1 |
20060064159 | Porter et al. | Mar 2006 | A1 |
20060081260 | Eells et al. | Apr 2006 | A1 |
20060118236 | House et al. | Jun 2006 | A1 |
20070038288 | Lye et al. | Feb 2007 | A1 |
20070078412 | McGuckin, Jr. et al. | Apr 2007 | A1 |
20070078416 | Eliasen | Apr 2007 | A1 |
20070078438 | Okada | Apr 2007 | A1 |
20070088336 | Dalton | Apr 2007 | A1 |
20070123811 | Squitieri | May 2007 | A1 |
20070135775 | Edoga et al. | Jun 2007 | A1 |
20070140797 | Armstrong | Jun 2007 | A1 |
20070142850 | Fowler | Jun 2007 | A1 |
20070161958 | Glenn | Jul 2007 | A1 |
20070167901 | Herrig et al. | Jul 2007 | A1 |
20070168019 | Amplatz et al. | Jul 2007 | A1 |
20070173868 | Bach et al. | Jul 2007 | A1 |
20070191779 | Shubayev et al. | Aug 2007 | A1 |
20070197856 | Gellman et al. | Aug 2007 | A1 |
20070213838 | Hengelmolen | Sep 2007 | A1 |
20070219510 | Zinn et al. | Sep 2007 | A1 |
20070233018 | Bizup et al. | Oct 2007 | A1 |
20070244539 | Lentz et al. | Oct 2007 | A1 |
20070249986 | Smego | Oct 2007 | A1 |
20070249987 | Gertner | Oct 2007 | A1 |
20070265584 | Hickman et al. | Nov 2007 | A1 |
20070293823 | Sherry | Dec 2007 | A1 |
20070293829 | Conlon et al. | Dec 2007 | A1 |
20080009781 | Anwar et al. | Jan 2008 | A1 |
20080027534 | Edwin et al. | Jan 2008 | A1 |
20080132924 | McGuckin | Jun 2008 | A1 |
20080167595 | Porter et al. | Jul 2008 | A1 |
20080221469 | Shevchuk | Sep 2008 | A1 |
20080306580 | Jenson et al. | Dec 2008 | A1 |
20090076587 | Cully | Mar 2009 | A1 |
20090137944 | Haarala et al. | May 2009 | A1 |
20090179422 | Werth | Jul 2009 | A1 |
20090227932 | Herrig | Sep 2009 | A1 |
20090234267 | Ross | Sep 2009 | A1 |
20090318895 | Lachner | Dec 2009 | A1 |
20100154800 | Chang et al. | Jun 2010 | A1 |
20100160718 | Villafana et al. | Jun 2010 | A1 |
20100198079 | Ross | Aug 2010 | A1 |
20100268188 | Hanson | Oct 2010 | A1 |
20100268196 | Hastings et al. | Oct 2010 | A1 |
20100292774 | Shalev | Nov 2010 | A1 |
20110015723 | Batiste et al. | Jan 2011 | A1 |
20110054312 | Bell et al. | Mar 2011 | A1 |
20110060264 | Porter et al. | Mar 2011 | A1 |
20110112482 | Redd | May 2011 | A1 |
20110208218 | Ball | Aug 2011 | A1 |
20110257609 | Bizup et al. | Oct 2011 | A1 |
20110264080 | Lim et al. | Oct 2011 | A1 |
20110295181 | Dann et al. | Dec 2011 | A1 |
20120059305 | Akingba | Mar 2012 | A1 |
20120065652 | Cully et al. | Mar 2012 | A1 |
20120078202 | Beling et al. | Mar 2012 | A1 |
20130060268 | Herrig | Mar 2013 | A1 |
20130338559 | Franano et al. | Dec 2013 | A1 |
20140018721 | Gage et al. | Jan 2014 | A1 |
20140094841 | Sutton et al. | Apr 2014 | A1 |
20140276215 | Nelson | Sep 2014 | A1 |
20140288638 | Knight et al. | Sep 2014 | A1 |
20140371779 | Vale et al. | Dec 2014 | A1 |
20150051532 | Tomko | Feb 2015 | A1 |
20150082604 | Cully et al. | Mar 2015 | A1 |
20150094744 | Aghayev | Apr 2015 | A1 |
20150150640 | Boyle et al. | Jun 2015 | A1 |
20160066954 | Miller et al. | Mar 2016 | A1 |
20160129177 | Herrig | May 2016 | A1 |
20160279317 | Gale | Sep 2016 | A1 |
20170020556 | Sutton et al. | Jan 2017 | A1 |
20190015627 | Hall et al. | Jan 2019 | A1 |
20190022368 | Hall et al. | Jan 2019 | A1 |
20190184151 | Herrig | Jun 2019 | A1 |
Number | Date | Country |
---|---|---|
4418910 | Dec 1995 | DE |
29515546 | Mar 1997 | DE |
102008055587 | Aug 2009 | DE |
1797831 | Jun 2007 | EP |
62112567 | May 1987 | JP |
04507050 | Dec 1992 | JP |
05212107 | Aug 1993 | JP |
06105798 | Apr 1994 | JP |
09084871 | Mar 1997 | JP |
09264468 | Jul 1997 | JP |
2003501223 | Jan 2003 | JP |
3995057 | Oct 2007 | JP |
2008511414 | Apr 2008 | JP |
101026933 | Apr 2011 | KR |
1020110036848 | Apr 2011 | KR |
198403036 | Aug 1984 | WO |
199008509 | Aug 1990 | WO |
199519200 | Jul 1995 | WO |
199624399 | Aug 1996 | WO |
1998034676 | Aug 1998 | WO |
2000027299 | May 2000 | WO |
200076577 | Dec 2000 | WO |
200105447 | Jan 2001 | WO |
200105463 | Jan 2001 | WO |
2001028456 | Apr 2001 | WO |
2004032991 | Apr 2004 | WO |
2004112880 | Dec 2004 | WO |
2006026687 | Sep 2006 | WO |
2009059371 | May 2009 | WO |
2010059102 | May 2010 | WO |
2011060386 | May 2011 | WO |
2011153302 | Dec 2011 | WO |
2012143922 | Oct 2012 | WO |
2015100251 | Jul 2015 | WO |
Entry |
---|
Notice of Allowance dated Mar. 11, 2020 for U.S. Appl. No. 15/828,040. |
Office Action dated Oct. 17, 2019 for U.S. Appl. No. 15/828,040. |
Office Action dated Apr. 28, 2020 for U.S. Appl. No. 14/192,567. |
Office Action dated May 1, 2020 for U.S. Appl. No. 15/693,010. |
International Search Report and Written Opinion dated Apr. 4, 2019 for PCT/US2018/058179. |
Office Action dated Aug. 21, 2019 for U.S. Appl. No. 14/192,567. |
Office Action dated Sep. 26, 2019 for U.S. Appl. No. 15/693,010. |
Lin, et al., Contemporary Vascular Access Surgery for Chronic Haemodialysis, They Royal College of Surgeons of Edinburgh, J.R. Coll, Surg, Edinb., 41 ,Jun. 1996 ,164-169. |
Peterson, et al., Subclavian Venous Stenosis: A Complication of Subclavian Dialysis, The Journal of American Medical Association, vol. 252 No. 24 ,Dec. 28, 1994 ,3404-3406. |
Raju M.D., et al., Techniques for Insertion and Management of Complications, PTFE Grafts for Hemodialysis Access, Ann. Surg., vol. 206 No. 5 ,Nov. 1987 ,666-673. |
Sharafuddin, et al., Percutaneous Balloon-Assisted Aspiration Thrombectomy of clotted ahemodialysis Access Grafts, Journal of Vascular and Interventional Radiology, vol. 7 No. 2 ,Mar.-Apr. 1996, 177-183. |
European Search Report dated Jun. 8, 2005 for EP05006233.0. |
European Search Report dated Dec. 3, 2013 for EP05793066.1. |
International Preliminary Report dated Mar. 12, 2014 for PCT/US2012/053967. |
International Search Report and Written Opinion dated Jan. 18, 2019 for PCT/US2018/041821. |
International Search Report and Written Opinion dated Jan. 28, 2015 for PCT/US2014/049547. |
International Search Report and Written Opinion dated Mar. 15, 2013 for PCT/US2012/053967. |
International Search Report and Written Opinion dated Mar. 16, 2015 for PCT/US2014/046630. |
International Search Report and Written Opinion dated May 2, 2018 for PCT/US2018/013326. |
International Search Report and Written Opinion dated May 3, 2013 for PCT/US2012/053967. |
International Search Report and Written Opinion dated May 6, 1998 for PCT/US1998/001939. |
International Search Report and Written Opinion dated Jun. 3, 2009 for PCT/US2009/035923. |
International Search Report and Written Opinion dated Jun. 15, 2018 for PCT/US2018/020614. |
International Search Report and Written Opinion dated Jun. 20, 2007 for PCT/US2006/044564. |
International Search Report and Written Opinion dated Jul. 17, 2018 for PCT/US2018/023956. |
International Search Report and Written Opinion dated Oct. 30, 2018 for PCT/US2018/042900. |
International Search Report and Written Opinion dated Jun. 22, 2018 for PCT/US2018/014371. |
Notice of Allowance dated Mar. 15, 2010 for U.S. Appl. No. 11/216,536. |
Notice of Allowance dated Oct. 4, 2013 for U.S. Appl. No. 12/831,092. |
Notice of Allowance dated Oct. 5, 2018 for U.S. Appl. No. 15/093,622. |
Notice of Allowance dated Nov. 6, 2018 for U.S. Appl. No. 14/995,270. |
Office Action dated Jan. 8, 2019 for U.S. Appl. No. 15/035,626. |
Office Action dated Jan. 9, 2018 for U.S. Appl. No. 14/450,468. |
Office Action dated Feb. 6, 2013 for U.S. Appl. No. 12/831,092. |
Office Action dated Feb. 21, 2017 for U.S. Appl. No. 14/192,567. |
Office Action dated Mar. 15, 2018 for U.S. Appl. No. 14/332,091. |
Office Action dated May 5, 2010 for U.S. Appl. No. 10/962,200. |
Office Action dated May 24, 2018 for U.S. Appl. No. 14/995,270. |
Office Action dated Jun. 4, 2018 for U.S. Appl. No. 14/192,567. |
Office Action dated Jun. 9, 2016 for U.S. Appl. No. 14/192,567. |
Office Action dated Jun. 15, 2017 for U.S. Appl. No. 14/192,567. |
Office Action dated Jul. 11, 2018 for U.S. Appl. No. 14/450,468. |
Office Action dated Jul. 19, 2018 for U.S. Appl. No. 15/035,626. |
Office Action dated Aug. 7, 2017 for U.S. Appl. No. 14/450,468. |
Office Action dated Aug. 12, 2010 for U.S. Appl. No. 10/962,200. |
Office Action dated Aug. 15, 2016 for U.S. Appl. No. 14/332,091. |
Office Action dated Sep. 20, 2012 for U.S. Appl. No. 12/831,092. |
Office Action dated Oct. 1, 2018 for U.S. Appl. No. 14/332,091. |
Office Action dated Oct. 27, 2015 for U.S. Appl. No. 14/192,567. |
Office Action dated Nov. 26, 2007 for U.S. Appl. No. 10/962,200. |
Office Action dated Dec. 5, 2017 for U.S. Appl. No. 14/995,270. |
Office Action dated Dec. 5, 2018 for U.S. Appl. No. 14/450,468. |
Office Action dated Dec. 7, 2018 for U.S. Appl. No. 14/192,567. |
Office Action dated Dec. 20, 2017 for U.S. Appl. No. 14/192,567. |
Office Action dated Dec. 30, 2016 for U.S. Appl. No. 14/450,468. |
Clinical Reveiw of MTI, Onxy Liquid Embolization System, available at http://www.fda.gov/ohrms/dockets/ac/03/briefing/3975b1-02-clinical-review.pdf. accessed Aug. 29, 2005. |
Besarab, et al., Measuring the Adequacy of Hemodialysis Access, Current Opinion in Nephrology and Hypertension, Rapid Science Publishers ISSN ,1996 ,1062-4821. |
Coulson MD, et al., Modification of Venous End of Dialysis Grafts: An Attempt to Reduce Neointimal Hyperplasia, Dialysis & Transplantation, vol. 29 No. Jan. 1, 2000 ,10-18. |
Coulson MD, PHD, et al., A Combination of the Elephant Trunk Anastomosis Technique and Vascular Clips for Dialysis Grafts, Surgical Rounds ,Nov. 1999 ,596-608. |
Kanterman, et al., Dialysis Access Grafts: Anatomic Location of Venous Stenosis and Results of Angioplasty, Interventional Radiology, vol. 195 No. 1, 195 ,Apr. 1995 ,135-139. |
Kumpe, et al., Angioplasty/Thrombolytic Treatment of Failing and Failed Hemodialysis Access Sites: Comparison with Surgical Treatment, Progress in Cardiovascular Diseases, vol. XXXIV No. 4 ,Jan./Feb. 1992 ,263-278. |
Office Action dated Apr. 6, 2021 for U.S. Appl. No. 16/284,526. |
European Search Report dated Jul. 8, 2021 for EP18874078.1. |
Number | Date | Country | |
---|---|---|---|
20190126017 A1 | May 2019 | US |
Number | Date | Country | |
---|---|---|---|
62579228 | Oct 2017 | US |